NuCana plc
NuCana plc (NCNA): 12 pipeline candidates · 2 upcoming catalysts · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
N/A
D/E 0.23 · 0% dilution
Lead: Phase 2
12 candidates
2 upcoming, next in ~4663d
N/A
A transparent, data-derived signal for NuCana plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.7M
Cash
$24.3M
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| 5-fu | Phase 2 |
| fosifloxuridine nafalbenamide | Phase 1/Phase 2 |
| leucovorin | Phase 1/Phase 2 |
| nuc-3373 | Phase 1/Phase 2 |
| nuc-3373 + leucovorin | Phase 1/Phase 2 |
| nuc-7738 | Phase 1/Phase 2 |
| nufiri | Phase 1/Phase 2 |
| nufiri + egfr inhibitor | Phase 1/Phase 2 |
| nufiri + vegf pathway inhibitor | Phase 1/Phase 2 |
| nufox | Phase 1/Phase 2 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$60K
| Holder | Shares | Value |
|---|---|---|
| glass jacobson investment advisors llc | 15,000 | $21K |
| citadel advisors llc | 13,855 | $20K |
| jane street group, llc | 10,511 | $15K |
| rhumbline advisers | 3,722 | $5K |
| morgan stanley | 2 | $3 |
| acadian asset management llc | 2 | $0 |
Frequently asked questions
How many drug candidates are in NuCana plc's pipeline?
NuCana plc (NCNA) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NuCana plc's lead drug candidate?
NuCana plc's most advanced tracked candidate is 5-fu (Phase 2) for Colorectal Cancer.
What is NuCana plc's next catalyst?
NuCana plc's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: KHAPZORY" — expected March 25, 2039.
What is NuCana plc's market capitalization?
NuCana plc's market capitalization is approximately $7.7M.
Who is the CEO of NuCana plc?
Mr. Hugh Stephen Griffith is the chief executive officer of NuCana plc (NCNA).
Get the full picture on NuCana plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.